Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) announced today that it has mailed to its shareholders the notice of special meeting and management information circular in connection with the special shareholder meeting to approve the amalgamation of Afexa and 1625907 Alberta Ltd. (the "Offeror"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant").

Afexa Life Sciences Inc. (“Afexa” or the “Company”) (TSX:FXA) - the maker of COLD-FX^® - announced today that it has been advised by 1625907 Alberta Ltd. (the “Offeror”), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”), that an additional 8,523,517 common shares (“Common Shares”) of Afexa were deposited to the Offeror’s offer (the “Valeant Offer”) to acquire all of the issued and outstanding Common Shares and that all such Common Shares have been taken up and will be paid for in accordance with the terms of the Valeant Offer.

Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^® - announced today that it has been advised by 1625907 Alberta Ltd. (the “Offeror”), a wholly-owned subsidiary of Valeant Pharmaceuticals, Inc. (“Valeant”), that 80,929,921 common shares (“Common Shares”) of Afexa were deposited to the Offeror’s offer (the “Valeant Offer”) dated October 3, 2011 to acquire all of the issued and outstanding Common Shares and that all such Common Shares have been taken up and will be paid for in accordance with the terms of the Valeant Offer. The Common Shares taken up under the Valeant Offer represent approximately 73.8% of the issued and outstanding Common Shares (on a fully-diluted basis). Afexa’s shareholders who tendered to the Valeant Offer will receive C$0.85 per share in cash which will be paid to Afexa’s shareholders in accordance with the terms of the Valeant Offer.

Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^® - announced today that it has filed a notice of change (the "Notice of Change") to its prior directors' circulars on SEDAR (available at www.sedar.com and on the Company's website www.afexa.com) in connection with:

EDMONTON, ALBERTA – Friday, September 30, 2011 - Afexa Life Sciences Inc. (“Afexa” or the “Company”) (TSX:FXA) - the maker of COLD-FX® - announced today that it has entered into an agreement (the “Agreement”) with Valeant Pharmaceuticals International, Inc. (“Valeant”) and 1625907 Alberta Ltd. (the “Offeror”), a wholly-owned subsidiary of Valeant, pursuant to which the Offeror has agreed to amend its offer dated September 6, 2011 to purchase all of the issued and outstanding common shares (the “Common Shares”) of Afexa. Pursuant to the amendment, holders of Common Shares will receive $0.85 in cash per share (the “Increased Valeant Offer”)...

Afexa Life Sciences Inc. (“Afexa” or the “Company”) (TSX:FXA) - the maker of COLD-FX^® - announced today that Paladin Labs Inc. (“Paladin”) has amended its offer for any and all of the common shares of Afexa (the “Amended Paladin Offer”) by way of a Notice of Variation and Extension dated September 26, 2011.  Under the Amended Paladin Offer, holders of common shares can elect either $0.81 per share in cash or 0.0217 of a Paladin share for each common share of Afexa. 

Paladin Labs Inc. ("Paladin" or the "Company")(TSX:PLB), a leading Canadian diversified specialty pharmaceutical company, today confirmed that it is increasing its offer to acquire any and all of the issued and outstanding common shares of Afexa Life Sciences Inc. ("Afexa")(TSX:FXA) to $0.81 per share (the "Enhanced Offer"), following today's order from the Alberta Securities Commission ("ASC") cease-trading Afexa's two shareholder rights plans, effective 12:01 am on September 30, 2011.

Afexa Life Sciences Inc. (“Afexa” or the “Company”) (TSX:FXA) - the maker of COLD-FX^® - responded to a news release issued today by Paladin Labs Inc. (“Paladin”) (TSX:PLB) announcing Paladin's intention to enhance its unsolicited takeover offer (“Offer”) for all and any of the outstanding shares of Afexa Life Sciences Inc. in the event that Afexa's two shareholder rights plans (dated January 25, 2010 and August 12, 2011) are waived by Afexa or cease-traded by the ASC within a reasonable time of a hearing to be held by the Alberta Securities Commission to consider an application made by Paladin to cease trade the rights plans. The hearing is scheduled for September 23, 2011.

Afexa Life Sciences Inc. (“Afexa” or the “Company”) (TSX:FXA) - the maker of COLD-FX^® - today announced that its Board of Directors (the “Board”) confirmed its previous recommendation that Afexa shareholders (the “Shareholders”) accept the offer by 1625907 Alberta Ltd. (“Acquireco”), a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”), pursuant to which Acquireco has agreed to acquire all of the outstanding common shares of Afexa for $0.71 per share in cash (the “Valeant Offer”).

Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA)- the maker of COLD-FX®- today announced that it has entered into a definitive acquisition support agreement (the "Agreement") with 1625907 Alberta Ltd. ("Acquireco"), a subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant") pursuant to which Acquireco has agreed to acquire all of the outstanding common shares of Afexa for $0.71 per share in cash (the "Valeant Offer").

Afexa Life Sciences Inc. (“Afexa” or the “Company”) (TSX:FXA) - the maker of COLD-FX^® - today announced that its Board of Directors (the “Board”) unanimously confirmed its previous recommendation that Afexa shareholders (the “Shareholders”) reject the unsolicited offer by Paladin Labs Inc. to acquire all of the outstanding shares of Afexa (the “Common Shares”) for either cash consideration of Cdn $0.55 per common share or 0.013 of a Paladin share for each common share (the “Paladin Offer”).

EDMONTON, ALBERTA--(Marketwire - Aug. 17, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX® - announces that it has been notified by the Toronto Stock Exchange (the "TSX") that the TSX will defer consideration of the acceptance of Afexa's new shareholder rights plan (the "Rights Plan") until such time as the TSX is satisfied that the appropriate securities commission will not intervene pursuant to National Policy 62-202 - Take-Over Bids - Defensive Tactics.

EDMONTON, ALBERTA – Sunday, August 14, 2011 - Afexa Life Sciences Inc. (“Afexa” or the “Company”) (TSX:FXA) - the maker of COLD FX^® - has adopted a new shareholder rights plan (the “New Rights Plan”). The New Rights Plan has been adopted to limit, to the extent possible, the ability of any investor to obtain effective control of Afexa through coercive and opportunistic methods without making a take-over bid offer to all shareholders of Afexa...

EDMONTON, ALBERTA – Wednesday, August 10, 2011 - Afexa Life Sciences Inc. (“Afexa” orthe “Company”) (TSX:FXA) - the maker of COLD-FX^® – was today advised that Paladin LabsInc. (“Paladin”) has filed documents with Canadian securities authorities formally commencingan unsolicited tender offer to acquire all of the outstanding common shares of the Company foreither cash consideration of Cdn.$0.55 per common share or 0.013 of a Paladin share for eachcommon share (“the Offer”).

EDMONTON, ALBERTA – Monday, July 18, 2011. On Friday, July 15, 2011, after market close, Paladin Labs Inc. announced in a news release that they had purchased 14.94% of Afexa’s total issued and outstanding common shares for a total beneficial ownership representing 15,421,300 common shares.